Pig Hearts Provide Long-Term Cardiac Function in Baboons

Primates receiving heart transplants from genetically engineered pigs have survived more than six months, a new study reveals.

Written byRuth Williams
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

© ISTOCK.COM, MORSA IMAGES

Hearts taken from pigs engineered so the organs won’t produce extreme immune reactions if transplanted into humans or other primates can support the life of recipient baboons for up to 195 days, according to a report in Nature today (December 5). The study, in which four baboons lived in good health for several months after surgery, brings xenotransplantation one step closer to the clinic, say researchers.

“I think this is an extremely important paper. It provides the longest survival yet of orthotopic heart [transplants] across the species barrier of pig to primate,” says transplantation specialist David Sachs of Columbia University Medical Center in New York who was not involved in the research. “Six months is a major jump forward.”

“With the survivorship that they’ve seen . . . there’s every reason to think that progression into the clinic is a worthwhile thing to do,” adds xenotransplantation ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • ruth williams

    Ruth is a freelance journalist. Before freelancing, Ruth was a news editor for the Journal of Cell Biology in New York and an assistant editor for Nature Reviews Neuroscience in London. Prior to that, she was a bona fide pipette-wielding, test tube–shaking, lab coat–shirking research scientist. She has a PhD in genetics from King’s College London, and was a postdoc in stem cell biology at Imperial College London. Today she lives and writes in Connecticut.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies